LONDON, Sept. 9, 2015 /PRNewswire/ -- Circulating tumor cells (CTCs) have tremendous utility in cancer research, aiding researchers in deciphering the complex processes leading to cancer metastasis and in developing more effective cancer therapeutics. Besides the research applications, the detection and analysis of CTCs has enormous potential in the diagnosis and management of cancer, as current tools, such as tumor tissue biopsy or imaging technologies, have numerous limitations. Although their biology and characteristics are still not entirely elucidated, CTCs are believed to detach from primary or secondary tumors, enter the bloodstream, and travel to distant organs. The majority of CTCs die in the bloodstream due to the harsh environment; very few of them are able to metastasize, and even fewer known as cancer stem cells (CSCs) can form distant tumors. Nevertheless, this small percentage of CTCs about 0.01% is sufficient to initiate and continue the blood-borne metastasis process, which leads to the progression of the disease and death.
The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is a detailed analysis of the potential opportunities for manufacturers of CTCs-based technologies, informing readers of the scientific basis of CTCs in an understandable fashion and constructing models of revenue opportunity based on several dimensions application area, cancer type and region that can assist with business planning efforts.
Download the full report: https://www.reportbuyer.com/product/3187705/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48